Removing Barriers, Restoring Hope: Transforming Access to Immunotherapy with IQVIA Patient Engagement and Support

Cancer patients face "financial and logistical barriers" that delay timely access to immunotherapy. IQVIA implemented a Patient Access Program (PAP) with a pharmaceutical company partner to "ensure eligible patients could begin and maintain their immunotherapy regimens without delay or disruption." No specific metrics or percentages are given on the page; full case detail is gated behind a PDF download.

The customer is anonymised in IQVIA’s own case study — not withheld by us.

IQVIA is the largest combined real-world-data and commercial-intelligence company in healthcare — its legacy IMS prescription and claims data underpins much of the industry's analytics.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.